Medpace Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Medpace Holdings, Inc. (MEDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $22.18 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-10
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $22.18M, a 58.51% increase from fiscal 2024.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $13.99M, a 289.64% increase from fiscal 2023.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $3.59M, a 31.31% decline from fiscal 2022.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $5.23M, a 0.83% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|
| 2025-12-31 | $22.18M 10-K · filed 2026-02-10 | |
| 2024-12-31 | $13.99M 10-K · filed 2026-02-10 | |
| 2023-12-31 | $3.59M 10-K · filed 2026-02-10 | |
| 2022-12-31 | $5.23M 10-K · filed 2025-02-11 | |
| 2021-12-31 | $5.18M 10-K · filed 2024-02-13 | |
| 2020-12-31 | $6.83M 10-K · filed 2023-02-14 | |
| 2019-12-31 | $12.12M 10-K · filed 2022-02-15 | |
| 2018-12-31 | $1.42M 10-K · filed 2021-02-16 | |
| 2016-12-31 | $1.38M 10-K · filed 2017-02-28 | |
| 2015-12-31 | $1.17M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |